Core Laboratories (NYSE:CLB) Issues Quarterly Earnings Results, Hits Expectations

Core Laboratories (NYSE:CLB) released its quarterly earnings results on Wednesday. The oil and gas company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16, FiscalAI reports. Core Laboratories had a net margin of 5.10% and a return on equity of 10.03%. The company had revenue of $132.08 million for the quarter, compared to analyst estimates of $131.87 million. During the same quarter last year, the business earned $0.22 earnings per share. The firm’s revenue was down 1.8% on a year-over-year basis.

Core Laboratories Trading Down 0.9%

Shares of CLB stock opened at $10.40 on Thursday. Core Laboratories has a 1-year low of $9.13 and a 1-year high of $20.36. The company has a market cap of $477.20 million, a price-to-earnings ratio of 18.57, a PEG ratio of 1.98 and a beta of 1.14. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.12 and a quick ratio of 1.55. The stock has a 50 day simple moving average of $11.07 and a 200-day simple moving average of $14.00.

Core Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 30th. Stockholders of record on Monday, November 9th will be paid a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, November 9th. Core Laboratories’s dividend payout ratio is presently 7.14%.

Insider Transactions at Core Laboratories

In related news, CEO Lawrence Bruno purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average price of $10.78 per share, with a total value of $53,900.00. Following the purchase, the chief executive officer owned 262,438 shares of the company’s stock, valued at $2,829,081.64. The trade was a 1.94% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.26% of the company’s stock.

Core Laboratories News Summary

Here are the key news stories impacting Core Laboratories this week:

• Positive Sentiment: Third-quarter revenue rose 6% sequentially to $132.1 million, slightly exceeding the roughly $131.9 million consensus estimate. Adjusted EPS of $0.16 was in line with some analyst estimates, while operating income excluding special items increased 35% sequentially. Core Lab Reports Third Quarter 2026 Results
• Positive Sentiment: The company repurchased 87,873 shares for approximately $1.1 million and approved a quarterly dividend of $0.01 per share, payable November 30 to shareholders of record November 9. Core Laboratories Approves Cash Dividend
• Neutral Sentiment: Core Laboratories guided to fourth-quarter revenue of $128.5 million to $134.5 million and EPS of $0.12 to $0.20. The range implies revenue could decline sequentially, although the midpoint remains broadly consistent with third-quarter results. Core Laboratories Fourth-Quarter Guidance
• Negative Sentiment: Year-over-year performance deteriorated: revenue fell 2%, adjusted EPS declined 27% from $0.22, and GAAP net income dropped to $5.5 million from $14.5 million. Free cash flow was only $1.7 million. Zacks characterized the $0.16 adjusted EPS result as below its $0.17 consensus estimate. Core Laboratories Q3 Earnings

Analyst Ratings Changes

Several equities research analysts have recently issued reports on CLB shares. Weiss Ratings lowered shares of Core Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 2nd. Johnson Rice upgraded Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research report on Thursday, August 13th. Finally, Wall Street Zen upgraded Core Laboratories from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Core Laboratories has an average rating of “Hold” and an average price target of $21.00.

About Core Laboratories

Core Laboratories N.V. (NYSE: CLB) is a global provider of proprietary reservoir description and production enhancement services and products for the energy industry. The company helps oil and natural gas producers evaluate reservoirs, improve well performance, and optimize the recovery of hydrocarbons.

Its reservoir description activities include geological and geochemical analysis, petrophysical services, core and fluid analysis, and laboratory testing used to characterize subsurface formations.